Glypican-3 (GPC3) is an emerging therapeutic target in hepatoma. A novel anti-GPC3 monoclonal antibody (YP7) has been generated through a combination of peptide immunization and high-throughput flow cytometry screening. YP7 binds cell-surface-associated GPC3 with high affinity and exhibits significant hepatoma xenograft growth inhibition in nude mice. The new antibody may have potential for hepatoma therapy. For additional information, see Ho et al., pp. 592-9.
A novel anti-GPC3 monoclonal antibody (YP7)
Laboratory of Molecular Biology